Anti-EphA1 (extracellular) Antibody (#AER-011) is a rabbit polyclonal antibody targeting the extracellular domain of EphA1, a receptor tyrosine kinase critical in neuronal signaling and cancer biology .
Western Blot: Detects EphA1 in human Jurkat T cells, HeLa (cervix adenocarcinoma), SH-SY5Y (neuroblastoma), and MCF-7 (breast adenocarcinoma) cells. Preincubation with BLP-ER011 abolishes detection .
Immunohistochemistry: Stains striatal neurons in rat brain sections. Blocking peptide suppresses staining, confirming specificity .
Live Cell Imaging: Labels EphA1 on the surface of intact human MCF-7 cells using AlexaFluor-594 secondary antibodies .
Flow Cytometry: Detects cell surface EphA1 in mouse J774 macrophages. The blocking peptide does not interfere with this application .
EphA1 belongs to the Eph receptor family, which binds ephrin ligands to regulate neuronal plasticity, immune function, and cancer progression . Forward signaling via EphA1 involves autophosphorylation and activation of downstream kinases (e.g., Src, Ras/Rho GTPases), while reverse signaling may influence neighboring cells .
| Species | Reactivity | Applications |
|---|---|---|
| Human | Yes | WB, IHC, Live cell imaging, Flow cytometry |
| Rat | Yes | WB, IHC |
| Mouse | Yes | WB, Flow cytometry |
EphA1 signaling is implicated in:
Neuronal Plasticity: Regulates synapse formation and repair .
Cancer Progression: Overexpression in breast, cervical, and neuroblastoma cancers .
EphA1 is distinct from ErbB family receptors (e.g., EGFR/ErbB1) , which bind different ligands (e.g., EGF) and mediate distinct signaling pathways. While EGFR is a type I RTK involved in cell proliferation, EphA1 primarily regulates cell-cell communication .
This antibody targets a protein that likely functions as a transcriptional activator. It binds to the GCC-box pathogenesis-related promoter element and may play a role in regulating gene expression in response to stress factors and components of stress signal transduction pathways.
Relevant Research:
ERF011 (also known as DEAR1, ATERF#011, or CEJ1) is a member of the DREB subfamily A-5 of ERF/AP2 transcription factor family in Arabidopsis thaliana. It functions as a transcriptional repressor involved in defense and freezing stress responses. There are 16 members in this subfamily including RAP2.1, RAP2.9, and RAP2.10 . The protein contains an EAR (ERF Amphiphilic Repression) motif which enables its transcriptional repression function .
According to product specifications, commercially available ERF011 antibodies are generally validated for Western Blot (WB) applications with typical recommended dilutions of 1:1000-1:2000 . Some antibodies may be suitable for additional applications such as ELISA, but this varies by manufacturer and specific antibody clone.
The expected molecular weight of DEAR1/ERF011 is approximately 17 kDa as indicated in product specifications . When performing Western blot analysis, this is the primary band size researchers should expect to observe when using a specific ERF011 antibody.
For optimal maintenance of antibody activity, the storage recommendations are:
Lyophilized form: Store at -20°C to -70°C
After reconstitution: Store at 4°C for up to 1 month
For long-term storage after reconstitution: Aliquot and store at -20°C
Avoid repeated freeze-thaw cycles that can degrade antibody quality
| Storage Condition | Temperature | Duration |
|---|---|---|
| Lyophilized | -20°C to -70°C | 12 months |
| Reconstituted | 4°C | 1 month |
| Long-term reconstituted | -20°C to -70°C | 6 months |
Reconstitution should be performed as follows:
Briefly centrifuge the vial before opening to collect all material at the bottom
Add 150 μL of sterile water to the lyophilized antibody
Gently mix to ensure complete dissolution
Once reconstituted, the antibody can be aliquoted to avoid repeated freeze-thaw cycles
For proper validation, use recombinant protein containing the peptide used for immunization. For example, in antibody validation studies:
Use 2.5 ng, 10 ng and 25 ng of recombinant protein containing the immunization peptide
Run on 12% SDS-PAGE
Transfer to nitrocellulose membrane for 1 hour
Block with 5% skim milk at RT or 4°C for 1 hour
Incubate with primary antibody at 1:1000 dilution overnight at 4°C
Use appropriate HRP-conjugated secondary antibody at 1:10000 dilution
Given that the ERF family contains multiple similar members, cross-reactivity is a significant concern. Take these steps to minimize it:
Use antibodies generated against unique epitopes (not conserved domains)
Perform peptide competition assays to confirm specificity
Include appropriate negative controls (tissues not expressing ERF011)
Consider using ERF011 knockout/mutant lines as negative controls
Verify results using multiple techniques (e.g., WB combined with qRT-PCR)
ERF011/ERF11 has been shown to interact with other transcription factors and proteins. To study these interactions:
Co-immunoprecipitation (Co-IP) approach:
For ERF-DELLA protein interactions specifically:
To investigate ERF011's function in transcriptional regulation during stress:
ChIP (Chromatin Immunoprecipitation) approach:
Time-course analysis:
This is a critical challenge due to the high sequence homology within the ERF family. Advanced approaches include:
Using a proximity ligation assay (PLA) combined with specific antibodies:
Multiple antibody approach:
False positives are a significant concern with antibodies against transcription factor families. The causes and solutions include:
Cross-reactivity with related ERF family members:
Non-specific binding:
ERF011/ERF11 expression and activity are highly regulated by environmental conditions. Variation in results may be due to:
Diurnal expression patterns:
Stress-specific regulation:
Rigorous validation is essential due to documented cases of antibody cross-reactivity. For conclusive validation:
Perform peptide competition assays:
Use genetic controls:
Correlation with mRNA expression:
ERF011/ERF11 plays a complex role in growth-stress balance:
Antagonistic relationship with ERF6:
Dual role in growth regulation:
Based on advancements in antibody technology, several approaches could enhance ERF011 research:
Development of heterodimer-specific antibodies:
Proximity ligation assay (PLA) for specific detection:
Advanced epitope selection: